AtorvaStatin Postpartum and Reduction of Cardiovascular risK
Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-15
Target enrollment:
Participant gender:
Summary
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.